What is HC Wainwright’s Estimate for Zymeworks Q1 Earnings?

Zymeworks Inc. (NYSE:ZYME) – Analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for shares of Zymeworks in a note issued to investors on Monday, March 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.43) for the quarter, up from their prior estimate of ($0.46). HC Wainwright currently has a “Neutral” rating and a $13.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.95) EPS.

Several other equities analysts have also weighed in on ZYME. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target for the company in a research note on Monday, December 16th. Citigroup lifted their price target on Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, March 7th. Wells Fargo & Company lifted their price target on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. Finally, Lifesci Capital started coverage on Zymeworks in a research note on Tuesday. They issued an “outperform” rating and a $30.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Zymeworks has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Zymeworks Stock Performance

NYSE ZYME opened at $11.70 on Wednesday. Zymeworks has a fifty-two week low of $7.97 and a fifty-two week high of $17.70. The stock has a 50-day simple moving average of $14.01 and a two-hundred day simple moving average of $13.66. The firm has a market capitalization of $814.05 million, a P/E ratio of -7.80 and a beta of 1.13.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its holdings in shares of Zymeworks by 6.1% during the 3rd quarter. State Street Corp now owns 1,171,777 shares of the company’s stock worth $14,706,000 after purchasing an additional 67,401 shares during the last quarter. Barclays PLC boosted its holdings in shares of Zymeworks by 476.3% during the 3rd quarter. Barclays PLC now owns 154,384 shares of the company’s stock worth $1,937,000 after purchasing an additional 127,595 shares during the last quarter. Vestal Point Capital LP lifted its holdings in Zymeworks by 39.8% in the third quarter. Vestal Point Capital LP now owns 615,000 shares of the company’s stock valued at $7,718,000 after acquiring an additional 175,000 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in Zymeworks by 93.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company’s stock valued at $9,403,000 after acquiring an additional 311,107 shares during the last quarter. Finally, FMR LLC lifted its holdings in Zymeworks by 84.2% in the third quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after acquiring an additional 1,525 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Ecor1 Capital, Llc bought 204,098 shares of the stock in a transaction dated Friday, January 10th. The shares were acquired at an average cost of $13.13 per share, for a total transaction of $2,679,806.74. Following the acquisition, the director now directly owns 15,411,078 shares in the company, valued at approximately $202,347,454.14. This trade represents a 1.34 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kenneth Galbraith sold 57,291 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $14.92, for a total value of $854,781.72. Following the transaction, the chief executive officer now owns 47,543 shares in the company, valued at approximately $709,341.56. This represents a 54.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders bought 603,539 shares of company stock worth $8,384,708 and sold 89,601 shares worth $1,336,847. 1.92% of the stock is owned by company insiders.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.